News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegerion Pharmaceuticals, Inc. (AEGR) Announces Publication in the Lancet of Data From Its Pivotal Phase III Study of Lomitapide in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)


11/2/2012 7:20:47 AM

CAMBRIDGE, Mass., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, today announced publication in the November 2nd online version of the Lancet of the 78 week data from the Company's pivotal Phase III study of lomitapide in adults patients with homozygous familial hypercholesterolemia (HoFH).

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES